Subclinical Atherosclerosis in Juvenile Systemic Lupus Erythematosus
1 other identifier
observational
70
0 countries
N/A
Brief Summary
The aim of this study is to evaluate subclinical atherosclerosis in children and adolescents with juvenile SLE by measuring carotid intima-media thickness (CIMT), and to determine its associations with traditional cardiovascular risk factors (dyslipidemia, hypertension, obesity) and non-traditional disease-related risk factors (disease activity, lupus nephritis, corticosteroid dose, disease duration).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jun 2026
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 16, 2026
CompletedFirst Posted
Study publicly available on registry
April 22, 2026
CompletedStudy Start
First participant enrolled
June 1, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2027
Study Completion
Last participant's last visit for all outcomes
August 1, 2027
April 22, 2026
April 1, 2026
1 year
April 16, 2026
April 16, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
CIMT values in JSLE patients compared to age- and sex-matched healthy controls.
Baseline
Eligibility Criteria
Childrens diagnosed with systemic lupus erythematosus
You may qualify if:
- \- Children and adolescents aged under 18 years diagnosed with JSLE according to the Systemic Lupus International Collaborating Clinics ( SLICC 2012 Criteria ).
- Disease duration of at least 6 months.
- Under regular follow-up at the study institution.
You may not qualify if:
- Patients with other autoimmune or connective tissue overlap diseases (e.g., mixed connective tissue disease, juvenile dermatomyositis).
- Patients with congenital heart disease or known structural cardiovascular abnormalities.
- Patients with chronic kidney disease stage 4 or 5.
- Patients currently receiving lipid-lowering therapy prior to enrolment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Doctor
Study Record Dates
First Submitted
April 16, 2026
First Posted
April 22, 2026
Study Start (Estimated)
June 1, 2026
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
August 1, 2027
Last Updated
April 22, 2026
Record last verified: 2026-04